Literature DB >> 26085652

A Novel Modulator of Kv3 Potassium Channels Regulates the Firing of Parvalbumin-Positive Cortical Interneurons.

Marcelo D Rosato-Siri1, Erika Zambello1, Chiara Mutinelli1, Nicoletta Garbati1, Roberto Benedetti1, Laura Aldegheri1, Francesca Graziani1, Caterina Virginio1, Giuseppe Alvaro1, Charles H Large2.   

Abstract

Kv3.1 and Kv3.2 high voltage-activated potassium channels, which display fast activation and deactivation kinetics, are known to make a crucial contribution to the fast-spiking phenotype of certain neurons. Pharmacological experiments show that the blockade of native Kv3 currents with low concentrations of tetraethylammonium or 4-aminopyridine impairs the expression of this firing phenotype. In particular, Kv3 channels are highly expressed by fast-spiking, parvalbumin-positive interneurons in corticolimbic brain circuits, which modulate the synchronization of cortical circuits and the generation of brain rhythms. Here, we describe a novel small molecule, (5R)-5-ethyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-2,4-imidazolidinedione (AUT1), which modulates Kv3.1 and Kv3.2 channels in human recombinant and rodent native neurons. AUT1 increased whole currents mediated by human Kv3.1b and Kv3.2a channels, with a concomitant leftward shift in the voltage dependence of activation. A less potent effect was observed on hKv3.3 currents. In mouse somatosensory cortex slices in vitro, AUT1 rescued the fast-spiking phenotype of parvalbumin-positive-fast-spiking interneurons following an impairment of their firing capacity by blocking a proportion of Kv3 channels with a low concentration of tetraethylammonium. Notably, AUT1 had no effect on interneuron firing when applied alone. Together, these data confirm the role played by Kv3 channels in the regulation of the firing phenotype of somatosensory interneurons and suggest that AUT1 and other Kv3 modulators could represent a new and promising therapeutic approach to the treatment of disorders associated with dysfunction of inhibitory feedback in corticolimbic circuits, such as schizophrenia.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26085652     DOI: 10.1124/jpet.115.225748

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Modulators of Kv3 Potassium Channels Rescue the Auditory Function of Fragile X Mice.

Authors:  Lynda El-Hassar; Lei Song; Winston J T Tan; Charles H Large; Giuseppe Alvaro; Joseph Santos-Sacchi; Leonard K Kaczmarek
Journal:  J Neurosci       Date:  2019-04-01       Impact factor: 6.167

2.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

3.  Physiological modulators of Kv3.1 channels adjust firing patterns of auditory brain stem neurons.

Authors:  Maile R Brown; Lynda El-Hassar; Yalan Zhang; Giuseppe Alvaro; Charles H Large; Leonard K Kaczmarek
Journal:  J Neurophysiol       Date:  2016-04-06       Impact factor: 2.714

Review 4.  Involvement of cortical fast-spiking parvalbumin-positive basket cells in epilepsy.

Authors:  X Jiang; M Lachance; E Rossignol
Journal:  Prog Brain Res       Date:  2016-06-07       Impact factor: 2.453

Review 5.  Kv3 Channels: Enablers of Rapid Firing, Neurotransmitter Release, and Neuronal Endurance.

Authors:  Leonard K Kaczmarek; Yalan Zhang
Journal:  Physiol Rev       Date:  2017-10-01       Impact factor: 37.312

Review 6.  Translational Neuroscience in Autism: From Neuropathology to Transcranial Magnetic Stimulation Therapies.

Authors:  Manuel F Casanova; Estate M Sokhadze; Emily L Casanova; Ioan Opris; Caio Abujadi; Marco Antonio Marcolin; Xiaoli Li
Journal:  Psychiatr Clin North Am       Date:  2020-04-08

7.  Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator.

Authors:  Puja K Parekh; Michelle M Sidor; Andrea Gillman; Darius Becker-Krail; Letizia Bettelini; Roberto Arban; Giuseppe S Alvaro; Erika Zambello; Chiara Mutinelli; Yanhua Huang; Charles H Large; Colleen A McClung
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

Review 8.  Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.

Authors:  Felipe V Gomes; Anthony A Grace
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

9.  Pharmacological modulation of Kv3.1 mitigates auditory midbrain temporal processing deficits following auditory nerve damage.

Authors:  Anna R Chambers; Nadia Pilati; Pooja Balaram; Charles H Large; Leonard K Kaczmarek; Daniel B Polley
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

10.  The translationally relevant mouse model of the 15q13.3 microdeletion syndrome reveals deficits in neuronal spike firing matching clinical neurophysiological biomarkers seen in schizophrenia.

Authors:  J Thelin; P Halje; J Nielsen; M Didriksen; P Petersson; J F Bastlund
Journal:  Acta Physiol (Oxf)       Date:  2016-08-16       Impact factor: 6.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.